Octreotide (SMS 201-995) is asomatostatin receptoragonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to thesomatostatin receptorand mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediatesapoptosisand may also be used in disease studies in acromegaly^[1][2].

Octreotide reverses the PA-induced alterations in Akt and GSK3β phosphorylation and expression of GS mRNA in HepG2 cells^[1]. Octreotide (10^-8mM, 6 hours) induces phosphorylated-glycogen synthase kinase 3β (GSK3β) phosphorylation and increases glycogen synthase (GS) activity^[3].

Octreotide significantly lowers the plasma glucose levels in the obese rats of the HFD group. Octreotide intervention significantly decreases the serum insulin concentration; however, there is no marked reduction in serum TG, TC, FFA, ALT and AST levels. Octreotide significantly inhibits the HOMA index. Octreotide decreases ipGTT and ipITT AUCs, but not significantly. Octreotide improves fat degeneration in rats with HFD-induced obesity and lipid droplet accumulation in PA-treated HepG2 cells. Octreotide promotes the phosphorylation of Akt and GSK3β and the expression of GS mRNA in rats with HFD-induced obesity^[1]. Octreotide reduces body weight and wet kidney weight compared with the vehicle-treated (CONT) group. PAS and Octreotide/PAS treatment decrease cAMP levels, but Octreotide alone does not in PCK rats. In the Octreotide/PAS group, there are a significantly fewer pS6-positive cells than in the PAS alone group^[2].

1019.24

Solid

C₄₉H₆₆N₁₀O₁₀S₂

83150-76-9

Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr (Disulfide bridge: Cys2-Cys7)

FCFWKTCT (Disulfide bridge: Cys2-Cys7)

奥曲肽

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture and light

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

H₂O : 100 mg/mL(98.11 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： PBS

  Solubility: 100 mg/mL (98.11 mM); Clear solution; Need ultrasonic